Drug intelligence / Profile preview

GATE-101

Development stage: Discontinued
Lead developer: Gate Neurosciences
Modality: Small Molecules
Administration: Intravenous

Overview

GATE-101 is a small molecule drug developed as an antagonist of metabotropic glutamate receptor 2 (mGluR2) and metabotropic glutamate receptor 3 (mGluR3). Its mechanism of action involves blocking these receptors, which are implicated in the modulation of neurotransmission in the central nervous system. The drug was primarily investigated for use in nervous system diseases, specifically major depressive disorder and idiopathic hypersomnia. Development was led by Gate Neurosciences. Clinical development reached Phase 1 trials, but the program has since been discontinued[1][2][3][4].

Targets

GRM2 (mGluR2)GRM3 (mGluR3)

Beyond the preview

Go deeper on GATE-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GATE-101.

Explore the full profile